

Swiss MS Researcher Meeting 2015 – Programme

Friday, October 30, 2015

BernExpo, Bern

Joint Meeting with Swiss Neurological Society, Oct. 29-30, 2015

<https://kongress.imk.ch/sng2015/Program>

MS-Society Session I

10.00 – 11.30, Congress 4

Chairs: Myriam Schluemp, Lausanne;

Nicole Schaeren-Wiemers, Basel; Melanie Greter, Zurich

- 10.00 – 10.05** **Opening**
Myriam Schluemp, Lausanne
- 10.05 – 10.15** **News from the Swiss MS-Society**
Christoph Lotter, Zurich
- 10.15 – 10.30** **The Swiss MS Registry (SMSR):
A New Addition to the Swiss MS Research Landscape**
Viktor von Wyl, Zurich
- 10.30 – 10.45** **Characterization of encephalitogenic CD8+ T cells in an animal model
of multiple sclerosis**
N Page, D Zehn, D Pinschewer, D Merkler;
Geneva, Lausanne, Basel, Geneva (CH)
- 10.45 – 11.00** **Oxysterols and human memory T lymphocytes: an attractive story**
A Clottu, F Chalmin, A Mathias, R Du-Pasquier, C Pot;
Geneva, Lausanne (CH)
- 11.00 – 11.15** **Endothelial ALCAM (CD166) is not required for encephalitogenic
T cell migration across the blood-brain barrier**
R Lyck, CB Wyss, M Abadier, C Matti, U Deutsch, S Tietz, M Rosito,
N Schaeren-Wiemers, T Zeis, G Enzmann, JA Weiner, B Engelhardt;
Bern (CH), Iowa City (US), Basel (CH)
- 11.15 – 11.30** **Spinal cord gray matter atrophy – a biomarker for MS progression**
R Schlaeger, N Papinutto, AH Zhu, I v Lobach, CJ Bevan, M Bucci,
A Castellano, JM Gelfand, JS Graves, AJ Green, KM Jordan, A Keshavan,
V Panara, WA Stern, HC v Buedingen, E Waubant, DS Goodin,
BAC Cree, SL Hauser, RG Henry;
Basel (CH), San Francisco and Berkeley (US)

11.30 – 13.15 **Lunch**

Symposium

11.45 – 12.45, Congress 1

Reshaping MS Therapy – Extending Possibilities

Chairs: Ludwig Kappos, Basel; Claudio Gobbi, Lugano

Organized by Biogen

11.45 – 11.50 Welcome & Introduction

Ludwig Kappos, Basel

11.50 – 12.10 Concept of Pegylation

Adam Czaplinski, Zurich

12.10 – 12.30 Results of the ADVANCE Study

Christian Kamm, Bern

12.30 – 12.40 Panel Discussion

Ludwig Kappos, Basel; Claudio Gobbi, Lugano

12.40 – 12.45 Closing Remarks

Claudio Gobbi, Lugano

Poster Viewing

12.45 – 13.45, Foyer 2 / Pofia

12.45 – 13.45 Multiple Sclerosis Posters: P02 – P21

14.00 – 14.15 Coffee Break

Multiple Sclerosis

14.15 – 15.45, Congress 1

Chairs: Renaud Du Pasquier, Lausanne; Tobias Derfuss, Basel

14.15 – 14.45 Role of microbiota in EAE and Human MS

Hartmut Wekerle, Munich (DE)

14.45 – 15.15 Pathogenesis of Human MS

Roland Martin, Zurich

**15.15 – 15.45 Current and evolving options in MS treatment –
can we rise to the challenge?**

Ludwig Kappos, Basel

MS-Society Session II**16.00 – 17.30, Congress 4**

Chairs: Myriam Schluemp, Lausanne;

Nicole Schaeren-Wiemers, Basel; Melanie Greter, Zurich

-
- 16.00 – 16.15** **Nogo-A-antibodies as a potential novel therapy for Multiple Sclerosis**
BV Ineichen, C Bleul, S Kapitza, O Weinmann, N Good, M Linnebank,
ME Schwab;
Zurich (CH)
- 16.15 – 16.30** **IDO competent plasmacytoid dendritic cells regulate CNS
autoimmunity**
C Lippens, F Duraes, D Birghouse, M Irla, W Reith, J Mandl, S Hugues;
Geneva (CH), Marseille (FR), Bethesda (US), Montreal (CA)
- 16.30 – 16.45** **Inhibition of T cell mediated neuroinflammation by Btn2a2, a novel
immunomodulatory molecule co-regulated with MHC class II genes**
K Sarter, E Leimgruber, F do Valle Duraes, L Guéry, F Gobet, S Hugues,
W Reith;
Geneva (CH)
- 16.45 – 17.00** **The Neurotrophic Hepatocyte Growth Factor Negatively Regulates
The Cytotoxic T-Lymphocyte Activity of Murine CD8+ T cells**
M Benkhoucha, N Molnarfi, G Schneiter, PH Lalive;
Geneva (CH)
- 17.00 – 17.15** **Extending the spectrum of anti-MOG antibody positive inflammatory
CNS disease: Results from the Swiss Lupus Cohort Study**
AK Pröbstel, M Thanei, AC Lecourt, L Branco, C Ribl, KF Koenig,
U Huynh-Do, C Chizzolini, L Kappos, M Trendelenburg, T Derfuss;
Basel, Lausanne, Bern, Geneva (CH)
- 17.15 – 17.30** **Poster Award**
The Swiss MS-Society will award a prize of CHF 500 for the best
poster presentation.

Posters**Foyer 2 / Pofia**

- P02 Development of a CNS in vitro model based on induced pluripotent stem cells derived from blood of multiple sclerosis patients**
S Perriot, G Perriard, A Mathias, M Canales, N Déglon, R Du Pasquier;
Lausanne (CH)
- P03 Mechanisms distinct from those used by CD4+ TEM cells regulate CD8+ TEM cell migration across the blood-brain barrier under flow conditions in vitro**
H Rudolph, A Klopstein, C Blatti, R Lyck, B Engelhardt;
Bern (CH), Mannheim (DE)
- P04 Characterisation of cells present in cerebrospinal fluid of MS patients and controls using Time-of-Flight mass cytometry**
NSR Sanderson, A Sylvain, C Rauld, L Raad, JM Carballido, T Derfuss; Basel (CH)
- P05 Increased ex-vivo antigen presentation profile of B cells in multiple sclerosis**
A Mathias, G Perriard, M Canales, C Soneson, M Delorenzi, M Schluemp,
RA Du Pasquier; Lausanne (CH)
- P06 Longitudinal analysis of topographic VEP in relapsing-remitting patients with multiple sclerosis**
M Hardmeier, F Hatz, Y Naegelin, C Schindler, L Kappos, M Seeck, C Michel,
P Fuhr; Basel, Geneva (CH)
- P07 Intensity-dependent impacts of exercise on cognitive functions in multiple sclerosis – preliminary results of a randomized controlled trial**
J Bansi, A Lampert, J Kesselring; Valens (CH)
- P08 Time to relapse and disability progression in a long-term cohort of people with clinically isolated syndrome and relapse-onset multiple sclerosis treated with disease-modifying drugs: a prospective nationwide survey in Switzerland**
C Lienert, A Schötzau, P Hänni, S Beer, M Pardini, M D'Souza, J Kuhle, L Kappos,
Ö Yaldizli; Basel (CH), Solothurn (CH), Valens (CH), Genova (IT)
- P09 Correlation of Nine Hole Peg Test and MS related corticospinal tract damage assessed by the triple stimulation technique**
O Findling, A Pfister, A Altermatt, Y Naegelin, K Rösler, P Fuhr, L Kappos,
T Sprenger; Basel, Bern (CH)
- P10 Spinal cord gray matter atrophy in early multiple sclerosis**
R Schlaeger, N Papinutto, AH Zhu, V Panara, I v Lobach, CJ Bevan, M Bucci, A
Castellano, JM Gelfand, JS Graves, AJ Green, KM Jordan, A Keshavan, WA Stern,
HC v Buedingen, E Waubant, DS Goodin, BAC Cree, SL Hauser, RG Henry;
Basel (CH), San Francisco and Berkeley (US)
- P11 The Swiss Multiple Sclerosis Registry (SMSR): a citizen science platform for MS research**
V von Wyl, N Steinemann, V Ajdacic, J Kuhle, C Vaney, M Puhon, C Lotter, B An-
derseck, K Beer, P Calabrese, R du Pasquier, B Engelhardt, C Gobbi, N Jolley, S
Kägi, P Kunszt, R Kurmann, K Luyckx, D Merkler, K Nedeltchev, I Rapold, S
Schippiling, M Schluemp, J Kesselring, and the Swiss Multiple Sclerosis Registry;
Zurich, Basel, Crans-Montana, Valens, Wil, Lausanne, Bern, Lugano, Geneva, Aar-
au (CH)

- P12 **The French version of the Multiple Sclerosis Questionnaire for Physiotherapists: a reliable and valid method for the evaluation of the treatment of persons with MS**
NA van der Maas, S Ferchichi-Barbey; Biel, Lausanne (CH)
- P13 **Patient Reported Questionnaire in MS Rehabilitation: Testing Responsiveness and Minimal Important Difference of the French Version of the Multiple Sclerosis Questionnaire for Physiotherapists**
NA van der Maas, S Ferchichi-Barbey; Biel, Lausanne (CH)
- P14 **The High-Dimensional TH Cell Landscape in Multiple Sclerosis**
FJ Hartmann, V Tosevski, C Krieg, D Mrdjen, T Olsson, B Becher, Zurich (CH), Stockholm (SE)
- P15 **Claudin 3-deficient C57BL/6 mice display intact brain barriers**
C Coisne, P Baden, I Lazarevic, C Blatti, S Tietz, RV Lyck, GU Enzmann, M Furuse, U Deutsch, B Engelhardt; Bern (CH), Okazaki (JP)
- P17 **Reprogramming inflammatory monocytes by antibodies to colony-stimulating factor 1 receptor prevents sickness behavior in inflammatory diseases**
A Müller, L Strauss, M Greter, H Gast, B Becher, A Fontana; Zurich, Bern (CH)
- P18 **Sterile inflammation in MS: Induction of cytokine production in human monocytes by T cell surface bioactive lipids**
R Carpintero, I Riezman, L Gruaz, H Riezman, D Burger; Geneva (CH)
- P19 **Comparison of subjective and objective adherence in patients with multiple sclerosis using RebiSmart™**
C Zecca, D Disanto, S Mühl, C Gobbi; Lugano, Zug (CH)
- P20 **The Role of the Junctional Adhesion Molecule (JAM)-B in the Pathogenesis of Experimental Autoimmune Encephalomyelitis**
S Tietz, B Imhof, U Deutsch, B Engelhardt; Bern, Geneva (CH)
- P21 **Assessing Short and Graphically the Mobility in MS and Other Neurological Disease with the new iPhone App Sagas 10**
C Vaney, N Forkel, R Hilfiker; Crans Montana, Sion (CH)

The programme and abstracts of the Swiss MS Researcher Meeting can be found on the website of the Swiss MS-Society (www.multiplesklerose.ch).